Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 10,332 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all
Active, not recruiting Not applicable Interventional

Activating Spinal Circuits to Improve Walking, Balance, Strength, and Reduce Spasticity

NCT05429736
View directory record Official record
Conditions
Incomplete Spinal Cord Injury, Spasticity, Muscle
Interventions
Motor Skill Training (MST), Transcutaneous Spinal Stimulation (TSS)
Behavioral · Device
Lead sponsor
Shepherd Center, Atlanta GA
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 3 Interventional

A Study of Pitolisant in Patients With Prader-Willi Syndrome

NCT06366464
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant tablet, Placebo tablet
Drug · Other
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00413777
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 5:36 AM EDT
Withdrawn Phase 2 Interventional

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

NCT04791228
View directory record Official record
Conditions
Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions
Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
Device · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency

NCT00157092
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
Aerosolized, Recombinant Alpha 1-Antitrypsin
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Long QT Syndrome and Sleep Apnea

NCT03678311
View directory record Official record
Conditions
Long QT Syndrome, Sleep Apnea
Interventions
Continuous Positive Airway Pressure (CPAP)
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 23, 2026, 5:36 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program

NCT01569971
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Assessment
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 30 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Not applicable Interventional

Strengthening Tourette Treatment OPtions Using TMS to Improve CBIT, a Double-blind, Randomized, Controlled Study

NCT05705999
View directory record Official record
Conditions
Tourette Syndrome
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

NCT01949311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of VV-14305 for the Treatment of Thyroid Eye Disease

NCT07404111
View directory record Official record
Conditions
Thyroid Eye Disease (TED)
Interventions
VV-14305, Sham (No Treatment)
Genetic · Other
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Livonia, Michigan • Las Vegas, Nevada • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Terminated Not applicable Interventional Results available

Acupuncture for Adults With Sickle Cell Disease (SCD): A Feasibility Study

NCT04156399
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Acupuncture
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

NCT00001034
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections, Gastrointestinal Diseases
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
17
States / cities
San Francisco, California • Denver, Colorado • Wilmington, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 5:36 AM EDT
Terminated No phase listed Observational

Left Ventricular Aneurysms in Children

NCT00268034
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Not applicable Interventional Results available

Post-bypass Prophylactic IVIG in Infants and Neonates

NCT02043379
View directory record Official record
Conditions
Hypogammaglobulinemia, Congenital Heart Disease
Interventions
IVIG, Placebo
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 6 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

NCT03842969
View directory record Official record
Conditions
Huntington Disease
Interventions
RO7234292 (RG6042)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • La Jolla, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 4 Interventional Results available

NAS Treatment - Opiate Versus Non-Opiate

NCT01734551
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Morphine, Clonidine
Drug
Lead sponsor
Henrietta Bada
Other
Eligibility
1 Day to 7 Days
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 23, 2026, 5:36 AM EDT
Recruiting No phase listed Observational

Orphan Europe Carbaglu® Surveillance Protocol

NCT03409003
View directory record Official record
Conditions
N-acetylglutamate Synthase (NAGS) Deficiency
Interventions
Not listed
Lead sponsor
Nicholas Ah Mew
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 23, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Eltrombopag for Fanconi Anemia

NCT03206086
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Eltrombopag
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
6 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 23, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study the Safety and Efficacy of DBI-001 Gel Versus Aqueous Gel

NCT05253755
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DBI-001, Aqueous gel
Biological
Lead sponsor
DermBiont, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Austin, Texas • Mill Creek, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 23, 2026, 5:36 AM EDT
Completed No phase listed Observational

Goal Attainment Scaling (GAS) Sub-Study

NCT06484426
View directory record Official record
Conditions
Alzheimer's Disease in Down Syndrome
Interventions
Not listed
Lead sponsor
LuMind IDSC Foundation
Other
Eligibility
35 Years and older
Enrollment
46 participants
Timeline
2021 – 2024
U.S. locations
5
States / cities
San Diego, California • Park Ridge, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

NCT01232543
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Product 0405
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

NCT04447417
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 23, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma

NCT03467789
View directory record Official record
Conditions
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions
Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 23, 2026, 5:36 AM EDT